GENFIT
TOWARDS BETTER MEDICINE

Corporate Presentation

Corporate Access and Biotech Showcase during JP Morgan Healthcare Conference
January 8 – 12, 2023

Disclaimer & Looking Forward Statement

IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY.
CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING ECONOMIC TRENDS AND PERFORMANCE IS BASED UPON OR DERIVED FROM INFORMATION PROVIDED BY THIRD-PARTY CONSULTANTS AND OTHER INDUSTRY SOURCES. WHILE GENFIT BELIEVES THAT SUCH INFORMATION IS ACCURATE AND THAT THE SOURCES FROM WHICH IT HAS BEEN OBTAINED ARE RELIABLE, GENFIT HAS NOT INDEPENDENTLY VERIFIED THE ASSUMPTIONS ON WHICH PROJECTIONS OF FUTURE TRENDS AND PERFORMANCE ARE BASED. IT MAKES NO GUARANTEE, EXPRESS OR IMPLIED, AS TO THE ACCURACY AND COMPLETENESS OF SUCH INFORMATION.

This presentation contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to GENFIT, including, but not limited to statements about GENFIT's corporate strategy and objectives, the potential sizes of the markets for primary biliary cholangitis (PBC), cholangiocarcinoma (CCA), acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE) and urea cycle disorder (UCD), potential market opportunities within these markets, GENFIT's development plans, expected regulatory approvals, including the ability to obtain accelerated pathways, and clinical timelines, as well as the outcome of the ELATIVE™ phase 3 trial of elafibranor in PBC. The use of certain words, including "believe, "potential," "expect" and "will" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, and efficacy of our product candidates, the progress, timing and results of our ongoing and planned clinical trials, timing and outcomes of review and approvals by regulatory authorities of our drug and diagnostic candidates, the impact of the COVID-19 pandemic, the effects of the competitive landscape, inflation and fluctuations in exchange rates and market and general economic conditions, and the Company's continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the French Autorité des marches financiers ("AMF"), including those listed in Section 2 "Risks Factors and Internal Control " of the Company's 2021 Registration Document ("Document d'Enregistrement Universel") filed with the AMF on April 29, 2022, which is available on GENFIT's website (www.genfit.com) and on the website of the AMF(www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Form 20-F document filed with the SEC on the same date, and subsequent filings and reports filed with the AMF or SEC, including the Half-Year Business and Financial Report at June 30, 2022 or otherwise made public, by the Company.

In addition, even if the Company's results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

About GENFIT

Mission & Expertise

- **Late-stage biopharmaceutical company** dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs
- **20+ years of expertise** from discovery phase to late-stage development
- **Strong track record** to develop long term collaboration: Ipsen, Genoscience Pharma, Labcorp, Terns Pharmaceuticals

Pipeline

Expanded pipeline of innovative assets, comprising 6 independent programs with diversified mechanisms of action in 6 key therapeutic areas, and 2 diagnostics programs:

- **1 Phase III readout in 2023**
- **3 programs in Phase II in 2023**
- **2 preclinical programs**
- **2 diagnostic programs**

Financials

- In 2021, **IPSEN** became one of GENFIT's largest shareholders, acquiring 8% of its share capital
- Cash position: **€163.6M** as of Sept 30, 2022

150+ employees

700+ patents
& patents application

Fully committed in the continuous improvement of our **CSR & ESG Performance**[1]

WE SUPPORT

PACTE

EURONEXT

Nasdaq

Euronext & NASDAQ listed: GNFT

Based in Lille, Paris, Zurich & Cambridge, MA

ELA: elafibranor, PBC: Primary Biliary Cholangitis, NTZ: nitazoxanide, ACLF: Acute on chronic liver failure, CCA: cholangiocarcinoma, UCD: Urea cycle disorder, OAD: Organic acidemia disorder, HE: Hepatic encephalopathy, NASH: Nonalcoholic steatohepatitis

1.Since 2021 GENFIT has been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labor, the environment and anti-corruption.

A new GENFIT, following execution of the 2021-2022 strategic plan

Leveraging GENFIT's strengths and experience in liver diseases…

- *in Research*
- *in Clinical development*
- *in Regulatory affairs*
- *in Pre-commercialization*

… to address the high unmet medical needs in several liver indications

Elafibranor as a Potential Treatment for PBC (1/3) – Positive Phase 2 data

Statistically significant treatment effects with both 80mg and 120mg doses on the primary end-point* of serum alkaline phosphatase (ALP) change from baseline

Change from baseline in ALP at week 12[1]



ALP % Change vs. baseline1



*Non-parametric randomization ANCOVA with baseline as covariate
*** P-value vs. placebo: <0.001

Elafibranor awarded Breakthrough Therapy designation by the FDA and Orphan Drug Designation by the FDA & EMA for PBC[2]

JOURNAL OF HEPATOLOGY
The Home of Liver Research

A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA[1]

Jörn Schattenberg *et. al.* | Journal of Hepatology. Feb. 2021

Note:* confirmed in mITT* set. mITT (All subjects w/ available baseline value and at least one post baseline value under treatment for ALP)=Placebo (N=15), Elafibranor 80mg (N=15), Elafibranor 120mg (N=14). Per Protocol Set = Placebo (N=14), Elafibranor 80mg (N=14), Elafibranor 120mg (N=13). ITT (intend to treat) = Placebo (N=15), Elafibranor 80mg (N=14), Elafibranor 120mg (N=15).
1. Schattenberg et al. J. of Hepatol. 2021, Vol. 74, Issue 6:1344-1354; **2**. GENFIT Corporate Press Release June 29, 2019 "GENFIT Announces FDA Grant of Breakthrough Therapy Designation to Elafibranor for the Treatment of PBC.".

Elafibranor is a competitive 2L candidate for PBC

	Elafibranor*[2] Phase 2a Week 12 Data NCT03124108 EudraCT2016-003817-80	
	80mg (N=15)	Placebo (N=14)
Composite endpoint *% responders, ALP<1.67 x ULN; Bili<ULN and ALP reduction >15%*	**67%** (p=0.001)	6.7%
Alkaline phosphatase *(% change vs baseline)*	**-48%** (p<0.001)	3%

	Ocaliva™[3], Phase 3 POISE Month 12 Data NCT01473524	
	10mg (N=73)	Placebo (N=72)
Composite endpoint *% responders, ALP<1.67 x ULN; Bili<ULN and ALP reduction >15%*	**47%** (p<0.001)	10%
Alkaline phosphatase *(% change vs baseline)*	**~-36%**** (p<0.001)	~-4%**

Note: Indirect Comparison of Selected Biochemical Endpoint[1]. Both studies were add-on investigational therapy to UDCA or monotherapy in patients unable to tolerate UDCA. 2L: Second-line. ***Elafibranor –** mITT: All subjects w/ available baseline value and at least one post baseline value under treatment for ALP. **These are estimations-based figures as reported data is based on actual change from Baseline n ALP (U/L) .Elafibranor is an investigational compound and has not been approved by any regulatory authority in any indication. Obeticholic acid is registered in US and EU under the trade name OCALIVA®, please refer to the approved PI and SmPC.
1. Data from referenced clinical trials; **2.** Schattenberg et al. J. of Hepatol. 2021, Vol. 74, Issue 6:1344-1354; **3**. Nevens, et al. NEJM 2016, 375(7):631-43.

Elafibranor as a Potential Treatment for PBC (2/3) – Commercial partnership with Ipsen

Terms of the deal

- *€120M upfront payment*
- *Up to €360M in milestone payments*
- *Tiered double-digit royalties of up to 20%*
- *8% shareholder of GENFIT via an equity investment of €28M with premium*
- *Ipsen will assume responsibility for all additional clinical development, including completion of the long-term extension period of the ELATIVE™ trial, and global* commercialization*

*With the exception of China, Hong Kong, Taiwan, and Macau where Terns Pharmaceuticals holds the exclusive license to develop and commercialize elafibranor

Elafibranor as a Potential Treatment for PBC (3/3) – Commercial opportunity

Addressable market for second line post UDCA[1]

Ballpark overall market size by 2030

- ***$2.3bn*** *US*
- ***$0.8bn*** *EU*
- ***$3.1bn*** *total*

Main assumptions

- *Prevalence: **52k** (EU5) and **54k** (US) for 40% of patients moving into 2L*
- *Drug gross price ranges per year: **~$30k** in EU5 in 2022 and **~$84k** in US expected to slightly evolve as competition will arise in second line*

1: source IQVIA

Today, 6 indications with high unmet medical need across 6 programs (4 clinical, 2 preclinical), with frequent milestones reporting expected in the coming three years



1. Reflects management's anticipated timelines, which are subject to change
2. Out-licensed to Terns Pharmaceuticals and Ipsen Pharmaceuticals
3. Repositioned molecule
4. In-licensed from Genoscience Pharma
5. www.labcorp.com/tests/504960/nashnext
6. All drugs under development are investigational compounds that have not been reviewed nor been approved by a regulatory authority in targeted indications

Our therapeutic programs at a glance – MoAs and supporting evidence for further development

ELAFIBRANOR in PBC

Dual agonist of PPARα/δ

PHASE 2 data

JOURNAL OF HEPATOLOGY

- *A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA (NCT03124108)*

IPSEN

- *In December 2021, Ipsen and GENFIT entered into exclusive licensing agreement for elafibranor*

VS-01 in ACLF

First-in-class liposomal-based technology

PHASE 1b data



- *Impact on overall liver disease severity*
- *Dose-dependent ammonia removal from the body*
- *Improvement in psychometric tests*
- *Reduction of ACLF metabolites*
- *Reduction of infection-related metabolites*

NTZ in ACLF

Antibiotic and anti-inflammatory activities

Preclinical data

- *Reduces LPS-induced inflammation in healthy rats*
- *Beneficial effects on liver function markers (bil, alb) in models of cirrhosis*
- *Reduces brain edema in models of ACLF (BDL)*
- *Reduces inflammation markers in models of ACLF (BDL)*
- *Improves survival in treatment models of Sepsis (CLP)*

GNS561 in CCA

Small molecule PPT1 inhibitor

PHASE 1b data

- *Antitumor activity in human cell lines (HCC, iCCA*)*
- *Decreases tumor number and size in transgenic HCC mouse model*
- *First-in-human effects of PPT1 inhibition using GNS561+ Ezurpimtrostat in patients with primary/secondary liver cancers[1]*



- *Autophagy promotes cancer cell survival, tumor growth and treatment resistance*
- *Combination of GNS561 w/ MEK inhibitor may block this survival by inhibiting late-stage autophagy*

VS-01 in UCD & OAD

Potential first-line peritoneal route treatment

Proof of concept



- *Potential first-line treatment for acute hyperammonemic crises*
- *Fast implementation – shorter lead time vs. SOC*
- *Gentle as less hemodynamic disturbances and no vascular access damage*
- *Administered outside the dialysis and intensive care units*
- *Ease of administration to children, allowing broader access to peripheral hospitals*

VS-02 in HE

Urease inhibitor

Proof of concept



- *Urease inhibitory activity in vitro over +15 screened hydroxamic acid derivatives*
- *Synthesis of lead candidate optimized and straightforward*

GENFIT

All references available in Pipeline Day presentations: NYC (ir.genfit.com/static-files/13662b8f-377c-483d-9a82-7bcffb14c0c2), Paris (ir.genfit.com/static-files/2f8d42ec-3057-4316-98fe-b50aa75e0dc9)
Video recording of these events available at: www.labourseetlavie.com/strategies/presentation-investisseurs/genfit-pipeline-days-5-et-19-octobre-2022-paris-nyc
*HCC patients-derived cells, iCCA patients-derived cells and cell lines **1-** https://www.genosciencepharma.com/2022/03/03/liver-cancer-phase-1b-clinical-results-publication/

Genfit JPM presentation

IQVIA perspective on the commercial opportunity of GENFIT's pipeline

January 2023

Disclaimer

- *IQVIA is not an "authorized person" for the purposes of the Financial Services and Markets Act 2000 ("FSMA") and does not provide investment advice or carry on any other regulated activity under Part II of the FSMA 2000 (Regulated Activities) Order 2001.*
- *Projections and related information contained herein are made and provided subject to the assumptions, methodologies, caveats, and variables described in this report. Proprietary and third party Source on which analyses are conducted are reasonably believed to be reliable. No warranty is made as to the completeness or accuracy of such third party Source or Data.*
- *This report, in part or in whole, is not intended to constitute investment advice, and is not a recommendation to purchase or not purchase, an endorsement of, or an opinion as to the value of, any security or any investment instrument of our client or any other entity.*
- *As with any attempt to estimate future events, projections, conclusions, and other information included herein are subject to certain risks and uncertainties, and are not to be considered guarantees of any particular outcome.*
- *This report shall not be published, nor shall any public references to IQVIA be made regarding these services or this report, without IQVIA's prior written approval, provided that, this report may be given to third party organizations as contemplated in the contract terms. When so provided, this report and the information herein must always be provided and used in its entirety, including this complete Disclaimer page.*
- *This report is subject to the IQVIA Standard Terms and Conditions.*

While keeping its footprint in hepatology, GENFIT is now moving to a diversified portfolio covering multiple rare liver related diseases with high unmet needs

Urea Cycle Disorders (UCD)

*UCDs are a set of **rare inherited metabolic conditions** in which there is a **full or partial deficiency** in the enzymes of the **urea cycle**, causing a defect in the metabolism of excess nitrogen, and leading to **hyperammonemia**.*

Organic Acidemia Disorders (OAD)

*OADS are a spectrum of **rare inherited disorders** characterized by **enzymatic defects** in metabolism of amino-acids or some fatty acids leading to **toxic, and potentially life-threatening accumulation** of by-products*

Hepatic Encephalopathy (HE)

*HE is **deterioration in brain** function when liver is unable to adequately remove **toxins** from the blood. It is often associated with **cirrhosis** and potentially **fatal***



Cholangiocarcinoma (CCA)

*CCA are malignancies of the biliary duct system that may originate in the liver or extrahepatic bile ducts . It is the **second most common liver cancer,** accounting for 10-20% of all liver cancers*

Primary Biliary Cholangitis (PBC)

*Primary biliary cholangitis (PBC) is **chronic and progressive cholestatic disease** of the liver. It is a rare autoimmune disease that can lead to **cirrhosis** if untreated*

Acute on Chronic Liver Failure (ACLF)

*ACLF is **acute** and **life-threatening** condition in patients with chronic liver disease with or without cirrhosis that may progress into **multiple organ failure** with associated **high risk of mortality** within 3 months if not treated. However, it is potentially reversible with treatment*

The recent Versantis investment is transformative, creating a sustainable platform for future therapies in liver and related disorders. GENFIT's know-how and expertise in physiopathology of liver failure and dysfunction will be the driving force in this success

The six pursued diseases have low epidemiology and could potentially be eligible for orphan designation

Estimated current prevalence (1:100,000)



- **PBC:** Elafibranor has been granted orphan designation and breakthrough therapy designation
- **CCA**: Pemigatinib, Infigratinib and Futibatinib (FGFR2 mutation) have had accelerated approval from FDA. GNS561 granted ODD
- **UCD**: DTX301 and Pegzilarginase have been granted ODD
- **OAD:** HST-5040 granted FDA Orphan Drug, Fast Track and Rare Pediatric Disease designations for the treatment of MMA(2) and PA(3)

Note (1) Defined as the number of cirrhosis patients with HE events leading to hospitalization per year (2) 1:100,000 newborn (<18 years old) Source: Robert S. Rahimi, MD Et Al. AJM, (2)methylmalonic acidemia; (3)PA - propionic acidemia

All 6 diseases have a high impact on patients' lives and high unmet needs

	Burden of disease		Unmet needs	
HE	• Potentially **life-threatening condition** • Significant impairments in **multiple health-related quality of life domains** (sleep disturbances, functional impairments)		• Current approved HE treatments are associated with **significant side effects and low compliance**	
ACLF	• **Mortality rate at 90 days of 50% in UE5[1] and 490% in US[2]** • High cost per hospitalization of 50k US$		• **No approved treatments for ACLF**	
PBC	• After development of symptoms (cholestasis), and without treatment, **survival duration ranges from 5 to 12 years** • Associated with symptoms that impair quality of life such as fatigue, emotional dysfunction, or pruritus (itching)		• UDCA in first line (40% suboptimal response). **Only OCA in second line with contraindications**	
CCA	• The prognosis is poor, with **median survival of ~6 months** in unresectable advanced CCA patients		• Despite increasing targeted therapies (e.g.: FGFR2, IDH1), **many patients with advanced CCA do not initiate therapy after chemo due to lack of efficacy**	
OAD	• Children are at constant risk of having episodes of **decompensation and encephalopathy throughout lives and life-threatening symptoms** • **Newborns who do not receive treatment are at risk of death**		• **No current approved therapy**	
UCD	• Symptoms like lethargy, abnormal motor function, which precedes first hyperammonemia are associated with **reduction of patient's QoL** • **5y Mortality rate in neonatal onset UCD cases was 24%[3]**		• Current approved UCDs treatments are **not effective or not approved for acute hyperammonemia**	

1- Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis | Gastroenterology 2013;144:1426 –1437; **2-** Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA - PubMed (nih.gov); **3-** Gillian Yeowell *et al.* The burden of pharmacological treatment on health-related quality of life in people with a urea cycle disorder: a qualitative study | Springer Open, Journal of Patient-Reported Outcomes **4-** A longitudinal study of urea cycle disorders | ScienceDirect - GENFIT - Corporate Access and Biotech Showcase during JP Morgan Healthcare Conference - January 2023

GENFIT has a well-balanced portfolio across disease areas with limited treatment options and lower development costs(1)

Portfolio

- **Diversified portfolio** with multiple assets and modes of action across various indications

Diseases areas

- **Six liver-related diseases** most(2) of which are **advanced, life threatening,** with high unmet needs
- **Easy diagnosis** with standard tests

Clinical development

- **Smaller trials** (in comparison to NASH)
- **Short clinical development timelines**, leading to shorter time to inflection points

Regulatory & reimbursement

- **Potential orphan designation and accelerated regulatory pathway**
- Some are **pediatric indications** with high unmet need

Moving from one asset in NASH into pipeline of assets across several diseases

Given high unmet needs and lower prevalence, the indications could benefit from accelerated regulatory pathways and lower development costs

Note: (1) in comparison to NASH, (2)CCA, OAD, ACLF, UCD

These 6 diseases represent an overall ~14 bn USD market opportunity

Ballpark overall market size by 2030, bnUSD



Assumptions(3)

- Prevalence: 155k (EU5) / 80k (US) for grade 1 / 2 ACLF patients
- Drug price could amount to $30-40k per patient in US and $10-20k in EU based given the economic burden of hospitalizations

- Hospitalizations per year: 195k (EU5) / 200k (US)
- Drug price ranges: analogues in acute ICU costs would potentially range from $15-20k in US and $7-15k in EU5 based on economic burden of hospitalizations

- Prevalence: 52k (EU5) / 54k (US) for 40% of patients moving to 2L
- Drug gross price ranges per year: ~$30k in EU5 in 2022 and ~$84k in US expected to slightly evolve as competition will arise in second line

- Prevalence: 15k (EU5) / 15k (US)
- Drug price ranges per month: [$500 – $9k] in EU5 and [$k – $30k] in US

- Prevalence: 1k (EU5) / 1.3k (US)
- Drug price ranges per year: [$500k - $700k] in US and [$300k - $500k] in EU5

- Incidence in newborns: 129 (US), 198 (EU5)
- Drug price ranges per year: [$96 – $81k] in EU5 and [$200 – $300k] in US

(1) Only acute HE considered in estimations (2) Addressable market for second Line post UDCA (3) Estimation calculations include duration of treatment, potential eligibility to drug treatment, compliance rates based on analogues in rare diseases, gross-to-net price estimate depending on therapeutic area & disease

Conclusion

- **Elafibranor**: only asset targeting both PPARα/δ receptors for PBC
- **VS-01**: First-in-class liposomal-based technology
- **VS-02**: novel urease inhibitor bringing a unique oral and colon active formulation for HE
- **GNS561**: novel MoA with autophagy inhibition for CCA

- **Orphan drug designation granted for** elafibranor (FDA/EMA), VS-01 (FDA) and GNS561 (FDA)
- **Breakthrough therapy designation** (Elafibranor)
- **Rare pediatric disease designation** (VS-01)
- Potential **priority review voucher** (VS-01)

- **~14 bn USD** cumulative market across all disease areas
- Limited competitive intensity in OAD, UCD and ACLF

Questions?